Ülke: Tayvan
Dil: Çince
Kaynak: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)
TROPICAMIDE;;PHENYLEPHRINE HCL
台灣參天製藥股份有限公司 台北市中山區松江路126號9樓之1 (86383884)
S01FA56
點眼液劑
PHENYLEPHRINE HCL (1212002310) 5MG; TROPICAMIDE (5224000400) 5MG
瓶裝
製 劑
限由醫師使用
SANTEN PHARMACEUTICAL CO., LTD. SHIGA PLANT 348-3, AZA-SUWA, OAZA-SHIDE, TAGACHO INUKAMIGUN, SHIGA, JAPAN JP
tropicamide, combinations
散瞳和睫狀肌麻痹
有效日期: 2028/09/04; 英文品名: MYDRIN-P
1978-06-06
1 Dilating eye drops used for examination Mydrin ® -P Ophthalmic Solution MYDRIN ® -P Tropicamide and Phenylephrine Ophthalmic Solution DOH Import No. 005728 CONTRAINDICATIONS (THIS PRODUCT IS CONTRAINDICATED IN THE FOLLOWING PATIENTS.) 1) Patients with glaucoma or those predisposed to ocular hypertension as evidenced by a narrow angle or shallow anterior chamber. [Acute angle-closure glaucoma may occur.] 2) Patients with a history of hypersensitivity to any ingredients of this product COMPOSITION, CHARACTERISTICS Product Name Mydrin ® -P Ophthalmic Solution Active Ingredients tropicamide phenylephrine hydrochloride Content (per 1 mL) 5mg 5 mg Additives e-aminocaproic acid, benzalkonium chloride, chlorobutanol, boric acid, hydrochloric acid, purified water pH 4.5~5.8 Ratio of osmotic pressure 0.9~1.1 Characteristics Colorless to light yellow, clear, sterile water-based ophthalmic solution INDICATION Mydriasis and cycloplegia CATEGORY This drug must be prescribed by a physician ADMINISTRATION AND DOSAGE For pupil dilation, usually 1-2 drops per time, or 1 drop each time at an interval of 3 to 5 minutes and 2 attempts in total. For cycloplegia, usually 1 drop each time at an interval of 3 to 5 minutes and 2 to 3 attempts in total. The dosage may be increased or decreased as appropriate depending on the symptoms. PRECAUTIONS 1. Careful administration (This product should be administered with care in the following patients) 1) Children [See “6. Pediatric Use” section] 2) Patients with hypertension [Symptoms may be aggravated due to hypertensive effect of phenylephrine] 3) Patients with atherosclerosis [Symptoms may be aggravated due to the hypertensive effect of phenylephrine] 4) Patients with heart disease, including coronary artery disease or heart failure [Symptoms may be aggravated due to the β 1 agonistic effect of phenylephrine] 5) Patients with diabetes [Symptoms may be aggravated due to gluconeogenesis promoting effect of phenylephrine] 6) Patients with hyperthyroidism [Since hyperthyroidism may be ac Belgenin tamamını okuyun